medigraphic.com

2002, Number 4

<< Back Next >>

Vet Mex 2002; 33 (4)

Immunolocalization of cathepsin B in chondrocytes and osteoclasts in equine dyschondroplasia (osteochondrosis)

Hernández VG, Valdés MA, Mora VF, Kawas GJ, Ramírez RR, Davies E, Jeffcott L

Language: English/Spanish
References: 48
Page: 395-408
PDF size: 130.06 Kb.


ABSTRACT

The enzyme cathepsin B was immunolocalized by immunofluorescence in articular cartilage and subchondral bone in both normal and dyschondroplastic samples obtained from young horses aged 1-5 years old. Distribution of the enzyme was variable in dyschondroplastic cartilage due to a general lack of zonal organization. A strong intracellular immunoreaction was observed in abnormal chondrocytes arranged in clusters in all of the zones of the dyschondroplastic cartilage. Conversely, in normal articular cartilage the expression of cathepsin B was low at the articular surface as well as the mid zone but higher in the majority of chondrocytes at the deep zone. No morphological differences were observed in osteoclasts of normal and pathological samples.


REFERENCES

  1. Lillich JD, Bertone AL, Malemud CJ, Weisbrode SE, Ruggles AJ, Stevenson S. Biochemical, histochemical, and immunohistochemical characterization of distal tibial osteochondrosis in horses. Am J Vet Res 1997;58:89-98.

  2. 2. Olsson SE, Reiland S. The nature of osteochondritis in animals. Acta Radiol 1978;358 (Suppl):299-306.

  3. 3. Pool RR. Difficulties in definition of equine osteochondrosis; differentiation of developmental and acquired lesions. Equine Vet J 1993;16:5-12.

  4. 4. Stromberg B, Rejno S. Osteochondrosis in the horse. I. A clinical and radiologic investigation of osteochondritis dissecans of the knee and hock joints. Acta Radiol 1978;358 (Suppl):139-152.

  5. 5. Savage CL, McCarthy RN, Jeffcott LB. Effects of dietary energy and protein on induction of dyschondroplasia in foals. Equine Vet J 1993,16:74-79.

  6. 6. Henson FMD, Davies ME, Jeffcott LB. Equine dyschondroplasia (osteochondrosis)-histological findings and type VI collagen localization. Vet J 1997;154:53-63.

  7. 7. Jeffcott LB. Osteochondrosis in the horse-searching for the key to pathogenesis. Equine Vet J 1991;23:331-338.

  8. 8. Sires UI, Schmid TM, Fliszar CJ, Wang ZQ, Gluck SL, Welgus HG. Complete degradation of type X collagen requires the combined action of interstitial collagenase and osteoclast-derived cathepsin-B. J Clin Invest 1995;95:2089-2095.

  9. 9. Sasaki T, Ueno-Matsuda E. Cysteine-proteinase localization in osteoclasts: an immunocytochemical study. Cell Tissue Res 1993;271:177-179.

  10. 10. Morris EA, Treadwell BV. Effect of interleukin 1 on articular cartilage from young and aged horses and comparison with metabolism of osteoarthritic cartilage. Am J Vet Res 1994;55:138-146.

  11. 11. Roughley PJ, Nguyen Q, Mort JS, Hughes CE. Caterson, B. Proteolytic degradation in human articular cartilage: its relationship to stromelysin. In: Van der Berg WB, Van der Kraan, PM, Van Lent P.L.E.M, editors. Joint destruction in arthritis and osteoarthritis. Basel Switzerland. Birkhäuser, 1993:149-159.

  12. 12. Koolwijk P, Miltenburg AMM, Van Erck MGM, Oudshoorm M, Niedbala MJ, Breedvel FC, Van Hinsbergh VWM. Activated gelatinase-B (MMP-9) and urokinase-type plasminogen activator in synovial fluids of patients with arthritis. Correlation with clinical and experimental variables of inflammation. J Rheumatol 1995; 22:385-393.

  13. Van Noorden CJF, Smith RE, Rasnick D. Cysteine proteinase activity in arthritic rat knee joints and the effects of a selective systemic inhibitor, Z-Phe-Ala-CH2F. J Rheumatol 1988;15:1525-1535.

  14. Buttle DJ, Handley CJ, Ilic M, Saklatvala J, Murata M, Barret AJ. Inhibition of cartilage proteoglycan release by a specific inactivator of cathepsin B and inhibitor of matrix metalloproteinases: evidence for two converging pathways of chondrocyte-mediated proteoglycan degradation. Arth Rheumatol 1993;36:1709-1717.

  15. Buttle DJ, Bramwell H, Hollander AP. Proteolytic mechanisms of cartilage breakdown: a target for arthritis therapy. J Clin Mol Pathol Pathol: 1995;48:M167-M177.

  16. Morrison RIG, Barret AJ, Dingle JT, Prior D. Cathepsins B1 and D. Action on human cartilage proteoglycan. Biochem Biophys Acta 1973;302:411-419.

  17. Hernandez-Vidal G, Jeffcott LB, Davies ME. Immunolocalization of cathepsin B in equine dyschondroplastic growth cartilage. Vet J 1998;156:193-201.

  18. Goto T, Tsukuba T, Kiyoshima Y, Kato K, Yamamoto K, Tanaka T. Immunohistochemical localization of cathepsin B, D and L in the rat osteoclast. Histochemistry 1993;99:411-414.

  19. Soderstrom M, Salminen H, Glumoff V, Kirschke H, Aro H, Vuorio E. Cathepsin expression during skeletal development. Biochem Biophys Acta 1999;7;1446(1-2):35-46.

  20. Nguyen Q, Mort JS, Roughley PJ. Cartilage proteoglycan aggregate is degraded more extensively by cathepsin L than by cathepsin B. Biochem J 1990;266:569-573.

  21. Burleigh MC, Barret AJ, Lazarus GS. Cathepsin B1: A lysosomal enzyme that degrades native collagen. Biochem J 1974;137:387-398.

  22. Maciewicz RA, Wotton SF, Etherington DJ, Duance VC. Susceptibility of the cartilage collagens type II, IX and XI to the cysteine proteinases, cathepsins B and L. FEBS Letters 1991;269:189-192.

  23. Esser RE, Angelo RA, Murphey MD, Watts LM, Thornburg LP, Palmer JT, et al. Cysteine proteinase inhibitors decrease articular cartilage and bone destruction in chronic inflammatory arthritis. Arthritis Rheum 1994;37:236-247.

  24. Mort JS, Recklies AD, Poole AR. Extracellular presence of the lysosomal proteinase cathepsin B in rheumatoid synovium and its activity at neutral pH. Arthritis Rheum 1984;27:509-515.

  25. Baici A, Hörler D, Lang A, Merlín C, Kissling R. Cathepsin B in osteoarthritis: zonal variation of enzyme activity in human femoral head cartilage. Ann Rheum Dis 1995;54:281-288.

  26. Hernandez-Vidal G, Davies ME, Jeffcott LB. Localization of cathepsin B and D in equine articular cartilage. Pferdeheilkunde 1996;12:371-373.

  27. Hernandez-Vidal G. Immunolocalization and modulation of lysosomal enzymes in normal and dyschondroplastic equine cartilage (Ph.D. thesis). Cambridge (UK):University of Cambridge, 1997.

  28. Hernandez-Vidal G, Jeffcott LB, Davies ME. Cellular heterogeneity in cathepsin D distribution in equine articular cartilage. Equine Vet J 1997;29:267-273.

  29. Laemmli, UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.

  30. Buttle DJ, Bonner BC, Burnet D, Barrett AJ. A catalytically active high Mr form of human cathepsin B from sputum. Biochem J 1988;254:693-699.

  31. Humanson GL editor. Animal tissue techniques. 4th ed. San Francisco, California: WH Freeman and company,. 1979.

  32. Mankin HL, Lippiello L. Biochemical and metabolic abnormalities in articular cartilage from osteoarthritic human hips. J Bone Joint Surg Br. 1970;52A,:424-434.

  33. Poole CA, Matsuoka A, Schofield JR. Chondrons from articular cartilage III. Morphologic changes in the cellular microenvironment of chondrons isolated from osteoarthritic cartilage. Arthritis Rheum 1991;34:22-35.

  34. Pool RR, Meagher DM. Pathologic findings and pathogenesis of racetrack injuries. Vet Clin North Am Equine Pract 1990;6:1-30.

  35. Baici A, Lang A, Hörler D, Kissling R, Merlin C. Cathepsin B in osteoarthritis: cytochemical and histochemical analysis of human femoral head cartilage. Ann Rheum Dis 1995;54:289-297.

  36. Dodge GR, Poole AR. Immunohistochemical detection and immunochemical analysis of type II collagen degradation in human normal, rheumatoid, and osteoarthritic articular cartilage and in explants of bovine articular cartilage cultured with interleukin 1. J Clin Invest. 1989;83:647-661.

  37. McDevitt CA, Miller RR. Biochemistry, cell biology and immunology of osteoarthritis. Curr Opin Rheumatol 1989;1:303-314.

  38. Ali SY. The presence of cathepsin B in cartilage. Biochem J 1967;102:10-11.

  39. Ali SY, Bayliss MT. Enzymes involved in degradation of cartilage in osteoarthritis. Ann Rheum Dis 1975;34(2):65-66.

  40. Martel-Pelletier J, Cloutier JM, Pelletier JP. Cathepsin B and cysteine protease inhibitors in human osteoarthritis. J Orthop Res 1990;8:336-344.

  41. Trabandt A, Gay RE, Fassbender HG, Gay S. Cathepsin B in synovial cells at the site of joint destruction in rheumatoid arthritis. Arthritis Rheum 1991;34:1444-1451.

  42. Gabrijelcic D, Annan-Prah A, Rodic B, Rozman B, Cotic V, Turk V. Determination of cathepsin B and H in sera and synovial fluids of patients with different joint disease. J Clin Chem Clin Biochem 1990;28:149-153.

  43. Henderson B, Blake S. Connective tissue destruction in rheumatoid arthritis: therapeutic potential of selective metalloproteinase inhibitors. In: Davies ME, Dingle JT editors. Immunopharmacology of joints and connective tissue. London: Academic Press 1994:199-223.

  44. McDevitt CA, Pahl JA, Ayad S, Miller RR, Uratsuji M, Andrish JT. Experimental ostearthritic articular cartilage is enriched in guanidine-soluble type VI collagen. Biochem Biophys Res Commun 1988;157:250-255.

  45. Kuettner KE. Biochemistry of articular cartilage in health and disease. Clin Biochem 1992;25:155-163.

  46. Bonaldo P, Russo V, Buccioti F, Doliana R, Colombatti A. Structural and functional features of the a3 chain indicate a bridging role for chicken collagen VI in connective tissues. Biochem J 1990;29:1245-1254.

  47. Stallcup WB, Dahlin K, Healy P. Interaction of the NG2 chondroitin sulphate proteoglycan with type VI collagen. J Cell Biol 1990;111:3177-3188.

  48. Kominami E, Ueno T,Muno D, Katunuma N. The selective role of cathepsin B and D in the lysosomal degradation of endogenous and exogenous proteins. FEBS Letters 1991;287:189-192.




2020     |     www.medigraphic.com